Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

X
Trial Profile

A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Acronyms STRATUS
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 14 Jan 2021 Results of a pooled analysis (of data extracted from NCT01712789, NCT02773030, NCT01421524, NCT01191060 studies and Myeloma Genome Project) assessing multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma published in the Blood
    • 04 Aug 2020 Results (n=1110) of a comprehensive analysis assessing Cereblon changes from DNA and RNA samples extracted from myeloma cells and peripheral blood germline DNA collected at baseline and relapse from patients enrolled in four clinical studies: CC4074-MM010, CC220-MM001, CC122-ST-001MM2, IFM/DFCI-2009 and Myeloma Genome Project published in the Blood
    • 05 May 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top